bluebird bio Inc

Latest bluebird bio Inc News and Updates

  • uploads///BGNE
    Company & Industry Overviews

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///cells _
    Company & Industry Overviews

    Taking Stock of BeiGene’s Latest Performance

    BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///hospital _
    Company & Industry Overviews

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Intellia Therapeutics Stock Fell 9.8% on Monday

    On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.

    By Mike Benson
  • uploads///AKCA
    Company & Industry Overviews

    Exploring the Financial Performance of Akcea Therapeutics

    In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Analysts’ Recommendations for Akcea and Its Peers in March

    Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.

    By Kenneth Smith
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
  • uploads///Graph naglazyme
    Company & Industry Overviews

    Naglazyme: One of the Costliest Drugs in the United States

    The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.

    By Jillian Dabney
  • uploads///Graph Part
    Company & Industry Overviews

    Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week

    Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.

    By Peter Neil
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.